Chengdu, China, January 8, 2022
Dr. Allen, VP of Anticancer Bioscience, presented his insights on personalized / precision medicine at a roundtable discussion organized by Pharma's Almanac
Chengdu, China, January 8, 2022 – Dr. Thaddeus Allen, VP of Translational Biology and Business Development, was invited for a roundtable discussion by Pharma’s Almanac on January 7th, 2022. The topic of the discussion among a panel of scientists and various other expertise from pharma companies including Anticancer Bioscience (ACB) was to offer their insights on the most essential technological innovations that would make precision medicine a bench to bedside reality. Due to his expertise in precision oncology, Dr. Allen at ACB was invited to address key questions on personalized and precision medicine. The discussion further advanced in understanding as to which therapeutic area would evolve the most in the years to come.
Dr. Allen intellectually emphasized that the one-size-fits-all approach is not always logical, especially when it comes to cancer treatments. The rationale for this view is that cancer cells are known for heterogeneity, even within a tumor the individual cancer cells may harbor distinct genomic and epigenomic aberrations during their evolution. Modern therapeutics approaches like oncoprotein-targeted therapies, immunotherapies and synthetic lethal drugs would aid in the advancement of personalized medicine. He also highlighted that this could be within the realm of reality when researchers and clinicians are well equipped with the novel screening methodology that predicates or monitors drug efficacy and a strong inclination to examine the biomarkers for every patient rapidly, economically, and periodically.
He quoted the success of the most recognizable synthetic lethal cancer therapeutics, PARP inhibitors (which are utilized in cancers with DNA-repair deficiencies) that have been clinically approved useful for breast cancer and ovarian cancer.Shedding light on how these drugs work, Dr. Allen mentioned that synthetic lethal drug development is achievable when the same cancer-associated transformations that facilitate carcinogenesis also introduce an excessive dependency on druggable proteins or pathways. He predicates that appreciably more synthetic lethal cancer drugs targeting the previously uncovered dependencies will be revealed in the coming years.
Anticancer Bioscience foresees the cancer therapeutic future to be principally governed by the synthetic lethal drug development. Click here and here to have a complete insight into the roundtable discussions on Personalized/Precision Medicine.
-ENDS-
For further information, please contact:
At the company
Anticancer Bioscience:
bd@anticancerbio.com
Media Relations
Scius Communications
Sue Charles
+44 (0) 7968 726585
sue@sciuscommunications.com
About Anticancer Bioscience
Anticancer Bioscience (ACB) is an international private company, commercializing discoveries emerging from China’s world-leading cancer research at the J. Michael Bishop Institute of Cancer Research. With pioneers in synthetic lethal approaches to precision oncology and experts in MYC biology and cell division, ACB was founded in 2016 in Chengdu, China. ACB is based on over 20 years of collaborative research between the founder Dr. Dun Yang and his Nobel laureate mentor Dr. J. Michael Bishop. It has raised CNY131M (around USD21M) and has around 50 employees in Chengdu, China, Hyderabad, India, Sydney, Australia, St Andrews, UK, and San Francisco, USA.
